These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10850749)

  • 1. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities.
    Bachynsky J; McCracken P; Lier D; Alloul K; Jacobs P
    Alzheimer Dis Assoc Disord; 2000; 14(2):102-11. PubMed ID: 10850749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of introducing propentofylline for the treatment of dementia in Sweden.
    Wimo A; Witthaus E; Rother M; Winblad B
    Clin Ther; 1998; 20(3):552-66; discussion 550-1. PubMed ID: 9663370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.
    Mielke R; Möller HJ; Erkinjuntti T; Rosenkranz B; Rother M; Kittner B
    Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S29-35. PubMed ID: 9769027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
    Marcusson J; Rother M; Kittner B; Rössner M; Smith RJ; Babic T; Folnegovic-Smalc V; Möller HJ; Labs KH
    Dement Geriatr Cogn Disord; 1997; 8(5):320-8. PubMed ID: 9298634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.
    Rother M; Erkinjuntti T; Roessner M; Kittner B; Marcusson J; Karlsson I
    Dement Geriatr Cogn Disord; 1998 Jul; 9 Suppl 1():36-43. PubMed ID: 9716243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials in dementia with propentofylline.
    Kittner B; Rössner M; Rother M
    Ann N Y Acad Sci; 1997 Sep; 826():307-16. PubMed ID: 9329701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propentofylline for dementia.
    Frampton M; Harvey RJ; Kirchner V
    Cochrane Database Syst Rev; 2003; (2):CD002853. PubMed ID: 12804440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group.
    Kittner B
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia.
    Ringheim GE
    Ann N Y Acad Sci; 2000 Apr; 903():529-34. PubMed ID: 10818548
    [No Abstract]   [Full Text] [Related]  

  • 10. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies.
    Saletu B; Möller HJ; Grünberger J; Deutsch H; Rössner M
    Neuropsychobiology; 1990-1991; 24(4):173-84. PubMed ID: 2135708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.
    Rother M; Kittner B; Rudolphi K; Rössner M; Labs KH
    Ann N Y Acad Sci; 1996 Jan; 777():404-9. PubMed ID: 8624121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
    Lachaine J; Beauchemin C; Legault M; Bineau S
    Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-controlled trial of the xanthine derivative propentofylline in dementia.
    Möller HJ; Maurer I; Saletu B
    Pharmacopsychiatry; 1994 Jul; 27(4):159-65. PubMed ID: 7972348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.
    Willan AR; Goeree R; Pullenayegum EM; McBurney C; Blackhouse G
    Pharmacoeconomics; 2006; 24(1):93-106. PubMed ID: 16445306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials.
    Kittner B; De Deyn PP; Erkinjuntti T
    Ann N Y Acad Sci; 2000 Apr; 903():535-41. PubMed ID: 10818549
    [No Abstract]   [Full Text] [Related]  

  • 16. [New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)].
    Kapl D; Rudolphi KA
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 1998 Sep; 26(5):317-21. PubMed ID: 9931990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of an in-home respite care program in supporting informal caregivers of people with dementia: design of a comparative study.
    Vandepitte S; Van Den Noortgate N; Putman K; Verhaeghe S; Annemans L
    BMC Geriatr; 2016 Dec; 16(1):207. PubMed ID: 27912740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia.
    Mielke R; Kittner B; Ghaemi M; Kessler J; Szelies B; Herholz K; Heiss WD
    J Neurol Sci; 1996 Sep; 141(1-2):59-64. PubMed ID: 8880694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the societal impact of acetylcholinesterase inhibitor therapies.
    Winblad B; Wimo A
    Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S9-19. PubMed ID: 10622674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.